PGR (Progesterone receptor)

P2, N=60, Recruiting, University of Texas Southwestern Medical Center | Trial primary completion date: Apr 2026 --> Apr 2027

P1, N=60, Recruiting, Immunomic Therapeutics, Inc.

HER2-low status was associated with worse OS in breast cancer patients with certain negative prognostic factors compared with HER2-zero status. Additionally, HER2-low1+ and HER2-low2+/ISH(-) subgroups predominantly exhibited HR+ status.

We developed and validated a well-calibrated nomogram for predicting DFS in patients with HR+/HER- breast cancer. This nomogram uniquely integrates MHR with clinicopathological factors to predict prognosis in HR+/HER2- breast cancer and can facilitate individualized therapeutic planning.

Postoperatively, he received adjuvant stereotactic radiosurgery (30-35 Gy in five fractions) to the resection cavity and was transitioned from tamoxifen to trastuzumab deruxtecan (T-DXd) for improved CNS-directed systemic therapy. Surveillance imaging at 6 months demonstrated no intracranial recurrence, and systemic restaging showed no extracranial disease progression. This case highlights the importance of prompt neuroimaging for new neurological symptoms in male breast cancer patients and supports a multimodal strategy, including surgical resection, focal radiation, and CNS-penetrant HER2-targeted therapy, for achieving durable intracranial control in select patients with isolated brain metastasis.

P1, N=30, Recruiting, University of Texas Southwestern Medical Center | Trial completion date: Apr 2026 --> Apr 2029 | Trial primary completion date: Apr 2026 --> Apr 2028

P2, N=134, Not yet recruiting, Virginia Commonwealth University

It aims to explain A2AR regulation across distinct tumor microenvironment (TME) compartments, and a critical analysis of its crosstalk with glycolytic metabolic checkpoints, which include hypoxia-inducible factor 1-alpha (HIF-1α) and AMP-activated protein kinase (AMPK). This provides insight into its potential for therapeutic targeting.

TN likely has a cytostatic effect selectively in TNBC cells, indicating functional suppression of tumorigenic properties. Further studies are required to elucidate the underlying mechanisms, and its potential use in combinatorial therapies.

This design assesses a CBT within a clinical environment while effectively eliminating any unwanted effects on patient care. This type of service evaluation provides a useful step to establish confidence in a CBT before trialing its effect on patient care. It also offers the opportunity to support interventional randomized controlled trials, health economic evaluations, and usability studies. This protocol will hopefully prove useful to others who wish to conduct a similar service evaluation at their own institution.

P1, N=32, Active, not recruiting, Patrick Dillon, MD | Recruiting --> Active, not recruiting

At 27 cm, this represents one of the largest MCN-L successfully managed using a purely laparoscopic approach. Complete excision remains essential due to the malignant potential of these lesions.